Close Menu

NEW YORK (GenomeWeb) – Hong Kong-based startup Take2 Health said today that it has licensed intellectual property from Grail for the early detection of nasopharyngeal carcinoma. Chinese University of Hong Kong researchers Dennis Lo, Rossa Chiu, and Allen Chan founded Take2 and have entered into a definitive agreement with Grail for the exclusive worldwide rights to an IP portfolio for early detection of NPC.

Additional details of the licensing agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center  has implemented a new capture-based application to accurately assess myeloid malignancies   by detecting complex variants in challenging genes  in a single experiment.